Epic Faces FTC Antitrust Investigation Amid AI Expansion at Annual Conference

This week was a pivotal one for Epic Systems, the electronic health record (EHR) behemoth. Despite facing an antitrust investigation from the Federal Trade Commission (FTC), Epic hosted its annual user group meeting (UGM) at its headquarters in Wisconsin. The event showcased the company’s latest advancements in artificial intelligence (AI), including a platform that allows hospitals to build and monitor their own AI agents.

Reports emerged last Friday that the FTC has launched an antitrust investigation into Epic, with several healthcare industry insiders confirming they have been contacted by investigators. The probe is reportedly focused on how Epic grants or restricts access to patient data and whether employment agreements limit employees from joining competing companies. In a statement to MedCity News, Epic denied engaging in any anticompetitive practices.

“Epic does more to support standards-based data-sharing than any other EHR vendor,” the company’s spokesperson said. “We were the first EHR to connect to TEFCA-the federally sponsored interoperability network-and the first to do standards-based diagnostic image exchange. We publish over 1,000 APIs and interfaces on open.epic for developers to exchange data with Epic. Nearly 3,000 apps use open.epic resources today.”

Despite the regulatory challenges, Epic’s UGM was a showcase of its ambitious AI initiatives. CEO Judy Faulkner unveiled Agent Factory, a platform that enables hospitals to create and manage their own AI agents. The company also introduced Cosmos Curiosity, a predictive tool that leverages Epic’s vast de-identified patient database to identify risks such as hospital readmissions and assist clinicians in addressing population-level health questions.

Inside the AI Revolution at Epic

One of Epic’s most significant new AI projects is Ergo, described as “healthcare intelligence” that combines human capabilities like judgment, empathy, and intuition with AI’s ability to analyze large EHR datasets and iterate rapidly. This tool aims to enhance clinical decision-making by providing insights derived from comprehensive patient data.

Epic also debuted a new AI assistant designed to help clinicians prepare for appointments by pulling together relevant patient information. The company further expanded the capabilities of its existing AI assistants-Art, Emmie, and Penny-which support clinicians, patients, and revenue cycle staff, respectively.

These advancements reflect Epic’s ongoing commitment to integrating AI into healthcare workflows. However, the FTC investigation casts a shadow over these innovations, raising questions about how the company manages data access and employee mobility. The regulatory scrutiny could have far-reaching implications for the industry, particularly as other EHR vendors and tech companies explore similar AI applications.

Why It Matters

The FTC’s probe into Epic highlights the growing tension between technological innovation and fair competition in the healthcare sector. As AI continues to transform how patient data is used and shared, ensuring that these practices are transparent and equitable becomes increasingly critical. The outcome of this investigation could set important precedents for how regulators approach antitrust issues in the rapidly evolving field of health technology.

For patients and healthcare providers, the stakes are high. Access to comprehensive and interoperable health data can lead to better patient outcomes and more efficient care delivery. However, if practices like those under scrutiny at Epic become widespread, they could stifle competition and innovation, ultimately harming both patients and providers.

As the investigation unfolds, it will be crucial to balance the benefits of AI-driven healthcare with the need for a fair and competitive market. The decisions made in this case could shape the future of how health data is managed and shared, impacting millions of lives across the country.